<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Valproic Acid</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00313</strong>&#160; (APRD00066, APRD00256, DB00510)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Valproic acid, supplied as the sodium salt valproate semisodium or divalproex sodium, is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (<span class="caps">CAS</span> number: 76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of <span class="caps">HIV</span> and various cancers.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00313/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00313/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00313.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00313.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00313.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00313.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00313.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00313">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>2-n-propyl-n-valeric acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>2-Propylpentanoic Acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>2-Propylvaleric Acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>4-heptanecarboxylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>di-n-propylacetic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Di-n-propylessigs&#228;ure</td><td>German</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dipropylacetic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>DPA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>n-DPA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Valproate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Valproins&#228;ure</td><td>German</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>VPA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Valproate Semisodium</strong>
          <div class="cas">76584-70-8</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000185/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000185/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: MSRILKIQRXUYCT-UHFFFAOYSA-M</li>
              <li>Monoisotopic Mass: 310.212004155</li>
              <li>Average Mass: 310.4047</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000185">DBSALT000185</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Convulex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Depacon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Depakene</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Depakine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Depakote</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Depakote ER</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Deprakine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Encorate</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Epilim</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Epival</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Stavzor</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Valcote</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Valparin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Valproic</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/enzyme-inhibitors">Enzyme Inhibitors</a></li>
<li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li>
<li><a href="/mesh/antimanic-agents">Antimanic Agents</a></li>
<li><a href="/mesh/gaba-agents">GABA Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>99-66-1</td></tr><tr><th>Weight</th><td>Average: 144.2114<br>Monoisotopic: 144.115029756</td></tr><tr><th>Chemical Formula</th><td>C<sub>8</sub>H<sub>16</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>NIJJYAXOARWZEE-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-propylpentanoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCC(CCC)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00313.gif?1265922770">show</a>(8.07 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organonitrogen Compounds</td></tr><tr><th>Class</th><td>Amines</td></tr><tr><th>Subclass</th><td>Polyamines</td></tr><tr><th>Direct parent</th><td>Polyamines</td></tr><tr><th>Alternative parents</th><td>Enolates; Carboxylic Acids</td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td>This compound belongs to the polyamines. These are compounds containing more than one amine group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome.</td></tr><tr><th>Pharmacodynamics</th><td>The relationship between plasma concentration and clinical response is not well documented. One contributing factor is the nonlinear, concentration dependent protein binding of valproate which affects the clearance of the drug. Thus, monitoring of total serum valproate cannot provide a reliable index of the bioactive valproate species. For patients with epilepsy, the therapeutic range is commonly considered to be 50 to 100 mcg/mL of total valproate. However, patients may be controlled at lower or higher doses. </td></tr><tr><th>Mechanism of action</th><td>Valproic Acid dissociates to the valproate ion in the gastrointestinal tract and then binds to and inhibits GABA transaminase. The drug's anticonvulsant activity may be related to increased brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. Valproic Acid may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. It is also a histone deacetylase inhibitor. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection.</td></tr><tr><th>Absorption</th><td>Rapid absorption from gastrointestinal tract. Although the rate of valproate ion absorption may vary with the formulation administered (liquid, solid, or sprinkle), conditions of use (e.g., fasting or postprandial) and the method of administration (e.g., whether the contents of the capsule are sprinkled on food or the capsule is taken intact), these differences should be of minor clinical importance under the steady state conditions achieved in chronic use in the treatment of epilepsy. Food has a greater influence on the rate of absorption of the Depakote tablet (increases Tmax from 4 to 8 hours) than on the absorption of Depakote sprinkle capsules (increase Tmax from 3.3 to 4.8 hours). Furthermore, studies suggest that total daily systemic bioavailability (extent of absorption) is the primary determinant of seizure control. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>11 L/1.73 m2 [total valproate]</li>
	<li>92 L/1.73 m2 [free valproate]</li>
</ul></td></tr><tr><th>Protein binding</th><td>Concentration-dependent, from 90% at 40 &#181;g/mL to 81.5% at 130 &#181;g/mL. Higher than expected free fractions occur in the elderly, in hyperlipidemic patients, and in patients with hepatic and renal diseases. It may also affect the extent of protein binding of other drugs such as phenytoin or carbamazepine. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Valproic Acid is metabolized almost entirely by the liver. In adult patients on monotherapy, 30-50% of an administered dose appears in urine as a glucuronide conjugate. Mitochondrial &#223;-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose. Usually, less than 15-20% of the dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose is excreted unchanged in urine.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Valproic Acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003336" target="_blank">Cytochrome P450 2A6</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li></ul></td><td><a href="/metabolites/DBMET00060">4-ene-Valproic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/60">Details</a></td></tr><tr><td>Valproic Acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003336" target="_blank">Cytochrome P450 2A6</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li></ul></td><td><a href="/metabolites/DBMET00061">5-Hydroxyvalproic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/61">Details</a></td></tr><tr><td>Valproic Acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003336" target="_blank">Cytochrome P450 2A6</a></li></ul></td><td><a href="/metabolites/DBMET00062">3-Hydroxyvalproic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/62">Details</a></td></tr><tr><td>Valproic Acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003336" target="_blank">Cytochrome P450 2A6</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li></ul></td><td><a href="/metabolites/DBMET00063">4-Hydroxyvalproic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/63">Details</a></td></tr><tr><td>Valproic Acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003538" target="_blank">UDP-glucuronosyltransferase 1-9</a></li>
<li><a href="/biodb/bio_entities/BE0003677" target="_blank">UDP-glucuronosyltransferase 1-3</a></li>
<li><a href="/biodb/bio_entities/BE0003544" target="_blank">UDP-glucuronosyltransferase 1-4</a></li>
<li><a href="/biodb/bio_entities/BE0003678" target="_blank">UDP-glucuronosyltransferase 1-10</a></li>
<li><a href="/biodb/bio_entities/BE0003682" target="_blank">UDP-glucuronosyltransferase 1-8</a></li>
<li><a href="/biodb/bio_entities/BE0004694" target="_blank">UDP-glucuronosyltransferase 1-6</a></li>
<li><a href="/biodb/bio_entities/BE0003679" target="_blank">UDP-glucuronosyltransferase 2B7</a></li>
<li><a href="/biodb/bio_entities/BE0004696" target="_blank">UDP-glucuronosyltransferase 2B15</a></li></ul></td><td><a href="/metabolites/DBMET00064">Valproic acid &#946;-<i>O</i>-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/64">Details</a></td></tr><tr><td>Valproic Acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00065">2-ene-Valproic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/65">Details</a></td></tr><tr><td>Valproic Acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00066">(3Z)-2-Propylpent-3-enoic acid (3Z-Ene-VPA)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/66">Details</a></td></tr><tr><td>Valproic Acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00067">(3E)-2-Propylpent-3-enoic acid (3E-Ene-VPA)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/67">Details</a></td></tr><tr><td>Valproic Acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01015">Valproic acid CoA</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1038">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00060">4-ene-Valproic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01106">2,4-Diene-VPA</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1196">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00063">4-Hydroxyvalproic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01107">2-n-Propyl-4-oxopentanoic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1197">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01107">2-n-Propyl-4-oxopentanoic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01108">2-Propylsuccinic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1199">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00061">5-Hydroxyvalproic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01109">2-Propylglutaric acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1200">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00062">3-Hydroxyvalproic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01110">3-Oxovalproic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1201">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00065">2-ene-Valproic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00062">3-Hydroxyvalproic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1202">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00062">3-Hydroxyvalproic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01110">3-Oxovalproic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1246">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Valproate is metabolized almost entirely by the liver. Less than 3% of an administered dose is excreted unchanged in urine. Mitochondrial &#223;-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose.</td></tr><tr><th>Half life</th><td>9-16 hours (following oral administration of 250 mg to 1000 mg) </td></tr><tr><th>Clearance</th><td><ul>
	<li>0.56 L/hr/1.73 m2 [plasma clearance, total valproate]</li>
	<li>4.6 L/hr/1.73 m2 [plasma clearance, free valproate]</li>
	<li>4.8 &#177; 0.17 L/hr/1.73 m2 [males, unbound clearance]</li>
	<li>4.7 &#177; 0.07 L/hr/1.73 m2 [females, unbound clearance]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 1098 mg/kg; Oral, rat: LD<sub>50</sub> = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems. The safety and tolerability of valproate in pediatric patients were shown to be comparable to those in adults. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9828</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9626</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7345</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9695</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7405</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9277</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8247</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7033</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5447</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8174</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9397</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.957</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9583</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9364</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9805
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.5266
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.8523
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8543 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9357
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9249
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Banner pharmacaps inc</li>
<li>Abbott laboratories pharmaceutical products div</li>
<li>Catalent pharma solutions llc</li>
<li>Par pharmaceutical inc</li>
<li>Rp scherer north america div rp scherer corp</li>
<li>Usl pharma inc</li>
<li>Alpharma uspd inc</li>
<li>Apotex inc richmond hill</li>
<li>High technology pharmacal co inc</li>
<li>Pharmaceutical assoc inc div beach products</li>
<li>Sun pharmaceutical industries inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Vintage pharmaceuticals llc</li>
<li>Wockhardt eu operations (swiss) ag</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li><a href="http://www.apothecon.nl">Apothecon</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.banpharm.com">Banner Pharmacaps Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li>Coupler Enterprises Inc.</li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hitechpharm.com">Hi Tech Pharmacal Co. Inc.</a></li>
<li><a href="http://www.impaxlabs.com">Impax Laboratories Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.noven.com">Noven Pharmaceuticals Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Association</li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.precisiondose.com">Precision Dose Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li>Professional Co.</li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>USL Pharma Inc.</li>
<li>Vangard Labs Inc.</li>
<li>Vintage Pharmaceuticals Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li>
<li>Xactdose Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>250 mg</td></tr><tr><td>Capsule, delayed release</td><td>Oral</td><td>125 mg, 250 mg, 500 mg</td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td>100 mg/mL</td></tr><tr><td>Solution</td><td>Oral</td><td>250 mg/5 mL</td></tr><tr><td>Syrup</td><td>Oral</td><td>250 mg/mL</td></tr><tr><td>Tablet, delayed release</td><td>Oral</td><td>125 mg, 250 mg, 500 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>250 mg, 500 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Valproic acid liquid</td><td>10.2USD</td><td>g</td></tr><tr><td>Depakene 250 mg capsule</td><td>2.21USD</td><td>capsule</td></tr><tr><td>Valproic acid 250 mg capsule</td><td>0.79USD</td><td>capsule</td></tr><tr><td>Depakene 250 mg/5ml Syrup</td><td>0.66USD</td><td>ml</td></tr><tr><td>Novo-Valproic 500 mg Enteric-Coated Capsule</td><td>0.54USD</td><td>capsule</td></tr><tr><td>Pms-Valproic Acid E.C. 500 mg Enteric-Coated Capsule</td><td>0.54USD</td><td>capsule</td></tr><tr><td>Apo-Valproic 250 mg Capsule</td><td>0.27USD</td><td>capsule</td></tr><tr><td>Mylan-Valproic 250 mg Capsule</td><td>0.27USD</td><td>capsule</td></tr><tr><td>Novo-Valproic 250 mg Capsule</td><td>0.27USD</td><td>capsule</td></tr><tr><td>Nu-Valproic 250 mg Capsule</td><td>0.27USD</td><td>capsule</td></tr><tr><td>Pms-Valproic Acid 250 mg Capsule</td><td>0.27USD</td><td>capsule</td></tr><tr><td>Ratio-Valproic 250 mg Capsule</td><td>0.27USD</td><td>capsule</td></tr><tr><td>Sandoz Valproic 250 mg Capsule</td><td>0.27USD</td><td>capsule</td></tr><tr><td>Valproic Acid 250 mg/5ml Syrup</td><td>0.16USD</td><td>ml</td></tr><tr><td>Valproic acid 250 mg/5 ml syr</td><td>0.15USD</td><td>ml</td></tr><tr><td>Depakene 50 mg/ml Syrup</td><td>0.11USD</td><td>ml</td></tr><tr><td>Apo-Valproic 50 mg/ml Syrup</td><td>0.06USD</td><td>ml</td></tr><tr><td>Pms-Valproic Acid 50 mg/ml Syrup</td><td>0.06USD</td><td>ml</td></tr><tr><td>Ratio-Valproic 50 mg/ml Syrup</td><td>0.06USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6511678</td><td>1999-06-18</td><td>2019-06-18</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>120-130 &#176;C</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>1.3 mg/mL</td><td>FDA label </td></tr><tr><td>logP</td><td>2.75</td><td>SANGSTER (1993)</td></tr><tr><td>logS</td><td>-1.86</td><td>ADME Research, USCD</td></tr><tr><td>pKa</td><td>4.8</td><td>FDA label </td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>2.36e+00 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.54</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.8</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-1.8</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>5.14</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>-1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>37.3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>40.25</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>17</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1774">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1771">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1772">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1773">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5533">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5534">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5535">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5536">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5537">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 30</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5538">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5539">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 50</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1714">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Daniel Aubert, Francis Blanc, Henri Desmolin, Michel Morre, Lucette Sindely, &#8220;Valproic acid preparations.&#8221; U.S. Patent US5017613, issued January, 1965.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=5017613&amp;tbm=pts" target="_blank">US5017613 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Rosenberg G: The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci. 2007 Aug;64(16):2090-103. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17514356">Pubmed</a></li>
	<li>Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM: Depletion of latent <span class="caps">HIV</span>-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19;366(9485):549-55. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16099290">Pubmed</a></li>
	<li>Schwartz C, Palissot V, Aouali N, Wack S, Brons NH, Leners B, Bosseler M, Berchem G: Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. Int J Oncol. 2007 Mar;30(3):573-82. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17273758">Pubmed</a></li>
	<li>Valentini A, Gravina P, Federici G, Bernardini S: Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther. 2007 Feb;6(2):185-91. Epub 2007 Feb 5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17218782">Pubmed</a></li>
	<li><span class="caps">FDA</span> label</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00399" target="_blank">D00399 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07185" target="_blank">C07185 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3121" target="_blank">3121 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505925" target="_blank">46505925 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.3009.html" target="_blank">3009 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=9926" target="_blank">9926 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL109" target="_blank">CHEMBL109 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC001659" target="_blank">DNC001659 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451846" target="_blank">PA451846 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2260654" target="_blank">2260654 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/depakene.htm" target="_blank">http://www.rxlist.com/cgi/generic2/depakene.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/valproate.html" target="_blank">http://www.drugs.com/cdi/valproate.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/dep1124.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/dep1124.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Valproic_Acid" target="_blank">Valproic_Acid <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N03AG01<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N03#N03">N03 &#8212; ANTIEPILEPTICS</a></li><li><a href="/atc/N03A#N03A">N03A &#8212; ANTIEPILEPTICS</a></li><li><a href="/atc/N03AG#N03AG">N03AG &#8212; Fatty acid derivatives</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:12.92</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=1OHY" target="_blank">1OHY <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00313.pdf?1265922796">show</a>(1.41 MB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00313.pdf?1265922736">show</a>(77.9 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Acetylsalicylic acid increases the effect of valproic acid.</td></tr><tr><td><a href="/drugs/DB06216">Asenapine</a></td><td>Valproate completely inhibits the glucuronidation of asenapine but does not effect its exposure. Dose adjustment is not necessary with concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Decreases the effect of valproic acid</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Clarithromycin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Erythromycin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00949">Felbamate</a></td><td>Felbamate, a CYP2C19 inhibitor, may decrease the metabolism of Valproic acid, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Felbamate is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB08909">Glycerol Phenylbutyrate</a></td><td>Valproic acid may induce hyperammonemia. Monitor ammonia levels closely when use of valproic acid is necessary in UCD patients.</td></tr><tr><td><a href="/drugs/DB06218">Lacosamide</a></td><td>Valproic acid toxicity may occur at any time during the treatment course and should be considered in patients with acute changes in mentation, especially if there has been a recent change in antiepileptic therapy.
</td></tr><tr><td><a href="/drugs/DB00555">Lamotrigine</a></td><td>Valproic acid may increase the adverse effects of Lamotrigine by increasing Lamotrigine serum concentration. The Lamotrigine dose should be reduced by 50% during concomitant therapy. Monitor for changes in Lamotrigine therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00186">Lorazepam</a></td><td>Valproic acid may increase the serum concentration of Lorazepam by reducing Lorazepam metabolism. The Lorazepam dose should be reduced by 50% during concomitant therapy. Monitor for increased Lorazepam effects and toxicity. </td></tr><tr><td><a href="/drugs/DB00393">Nimodipine</a></td><td>Valproic acid increases the effect of nimodipine</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may reduce the serum concentration of Valproic acid by increasing Valproic acid metabolism. Valproic acid dose adjustments may be required during concomitant therapy. Monitor Valproic acid serum concentrations, efficacy and toxicity if Rifampin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB06201">Rufinamide</a></td><td>Valproic acid may increase the therapeutic/toxic effects of Rufinamide. Consider alternate therapy or monitor for changes in Rufinamide serum concentrations, therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. Decreases clearance of rufinamide and is a selective inhibitor of human carboxylesterase thus increasing serum concentrations. </td></tr><tr><td><a href="/drugs/DB06207">Silodosin</a></td><td>Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Telithromycin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir decreases the concentration of Valproic acid. Monitor Valproid acid efficacy.</td></tr><tr><td><a href="/drugs/DB01080">Vigabatrin</a></td><td>Vigabatrin reduces serum concentrations of valproic acid by 8%. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Do not take with milk.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>